Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01268904
Recruitment Status : Unknown
Verified December 2010 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : December 31, 2010
Last Update Posted : December 31, 2010
Sponsor:
Information provided by:
Hillel Yaffe Medical Center

Brief Summary:
To evaluate the safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures as part of seizure treatment protocol in pediatric ER

Condition or disease Intervention/treatment
Status Epilepticus Drug: Valproate

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Prospective
Study Start Date : January 2011
Estimated Primary Completion Date : July 2013
Estimated Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures

Group/Cohort Intervention/treatment
Pediatric status epilepticus Drug: Valproate
Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures




Primary Outcome Measures :
  1. Safety of intravenous valproate in pediatric status epilepticus [ Time Frame: One week ]

Secondary Outcome Measures :
  1. Efficacy of intravenous valproate in pediatric status epilepticus [ Time Frame: One week ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pediatric inpatients and emergency patients
Criteria

Inclusion Criteria:

  • Child with clinical presentation of status epilepticus

Exclusion Criteria:

  • All others

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01268904


Contacts
Layout table for location contacts
Contact: Iyad Magadly, MD 972-4-6304331 magadly@gmail.com

Locations
Layout table for location information
Israel
Hillel Yaffe Medical Center
Hadera, Israel, 38100
Principal Investigator: Iyad Magadly, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center

Layout table for additonal information
Responsible Party: Iyad Magadly, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01268904    
Other Study ID Numbers: 0098-10-HYMC
First Posted: December 31, 2010    Key Record Dates
Last Update Posted: December 31, 2010
Last Verified: December 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Status Epilepticus
Seizures
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Valproic Acid
Anticonvulsants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs